---
title: "European stocks \"Eleven Arhats\" | 1. Simao rose about 6.5% in January, Novo Nordisk fell over 2.7%, Sanofi, Roche, and SAP rose by more than 13% at most"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/226811962.md"
description: "On January 31, ASML Holding's stock price rose by 2.26%, with a cumulative increase of 6.48% in January. Novo Nordisk's stock price increased by 0.60%, but it fell by 2.71% cumulatively in January. Novartis, Sanofi, and Roche Holdings rose by 1.90%, 0.75%, and 0.28%, respectively, with cumulative increases of 7.88%, 11.37%, and 11.94% in January. SAP rose by 0.17%, with a cumulative increase of 13.06%. In contrast, the stock prices of L'Oréal, Nestlé, and LVMH Group fell by 1.39%, 1.53%, and 1.72%, respectively"
datetime: "2025-01-31T19:51:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/226811962.md)
  - [en](https://longbridge.com/en/news/226811962.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/226811962.md)
generator: "portal-rs"
---

# European stocks "Eleven Arhats" | 1. Simao rose about 6.5% in January, Novo Nordisk fell over 2.7%, Sanofi, Roche, and SAP rose by more than 13% at most

On Friday (January 31), ASML Holding's stock price in Amsterdam (ASML.NA) closed up 2.26% at €722.70, with a cumulative increase of 6.48% in January.  
 Novo Nordisk's stock price in Copenhagen (NOVOB.DC) closed up 0.60% at 607.30 Danish Krone, with a cumulative decrease of 2.71% in January.  
 Novartis (NOVN.SW) closed up 1.90%, with a cumulative increase of 7.88% in January;  
 Sanofi (SAN.FP) closed up 0.75%, with a cumulative increase of 11.37% in January;  
 Roche Holding (ROG.SW) closed up 0.28%, with a cumulative increase of 11.94% in January;  
 AstraZeneca (AZN.LN) closed up 0.27%, with a cumulative increase of 8.37% in January;  
 GlaxoSmithKline's stock price in London (GSK.LN) closed up 0.21%, with a cumulative increase of 4.42% in January;  
 SAP (SAP.GR) closed up 0.17%, with a cumulative increase of 13.06% in January;  
 L'Oréal (OR.FP) closed down 1.39%, with a cumulative increase of 4.87% in January;  
 Nestlé (NESN.SW) closed down 1.53%, with a cumulative increase of 3.47% in January;  
 LVMH Group (MC.FP) closed down 1.72%, with a cumulative increase of 4.87% in January

### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [SAP.US](https://longbridge.com/en/quote/SAP.US.md)
- [NSRGF.US](https://longbridge.com/en/quote/NSRGF.US.md)
- [LVMUY.US](https://longbridge.com/en/quote/LVMUY.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)
- [ROG.US](https://longbridge.com/en/quote/ROG.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [ASML.US](https://longbridge.com/en/quote/ASML.US.md)
- [LRLCY.US](https://longbridge.com/en/quote/LRLCY.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [NSRGY.US](https://longbridge.com/en/quote/NSRGY.US.md)

## Related News & Research

- [BREAKINGVIEWS-For Novartis, M&A is both a disease and cure](https://longbridge.com/en/news/298726698.md)
- [Key facts: Novartis posts late-stage failures; keeps 5-6% CAGR](https://longbridge.com/en/news/298276336.md)
- [Novartis RNA drug falls short in rare muscle disease study](https://longbridge.com/en/news/298589584.md)
- [Novartis DM1 Trial Setback Offset by Progress in Neuromuscular Pipeline](https://longbridge.com/en/news/298303140.md)
- [Novartis announces trial setback on del-desiran drug](https://longbridge.com/en/news/298270154.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**